News articles about Genocea Biosciences (NASDAQ:GNCA) have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genocea Biosciences earned a media sentiment score of -0.08 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.4005404328133 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 – GNCA (finance.yahoo.com)
- IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Securities Class Action Lawsuit has been Filed on Behalf of Investors who Purchased and Suffered Losses in Genocea Biosciences, Inc. (finance.yahoo.com)
- URGENT: Monteverde & Associates PC Invites Genocea … – PR Newswire (press release) (prnewswire.com)
- Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- URGENT: Monteverde & Associates PC Invites Genocea Biosciences, Inc. Shareholders with Losses in Excess of $100,000 To Contac… (ih.advfn.com)
Shares of Genocea Biosciences (GNCA) traded down $0.07 during midday trading on Tuesday, reaching $1.09. 466,100 shares of the company’s stock traded hands, compared to its average volume of 585,626. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. Genocea Biosciences has a 1-year low of $1.03 and a 1-year high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same period last year, the company posted ($0.45) EPS. equities research analysts expect that Genocea Biosciences will post -1.91 EPS for the current year.
Several brokerages have commented on GNCA. Needham & Company LLC upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, July 24th. Cowen and Company restated an “outperform” rating and issued a $40.00 price objective on shares of Genocea Biosciences in a report on Tuesday, July 25th. ValuEngine lowered shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. Stifel Nicolaus lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $15.00 to $2.50 in a report on Monday, September 25th. Finally, Zacks Investment Research upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $7.62.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.